Purified oral cannabidiol for pain management in severe recessive dystrophic epidermolysis bullosa
- PMID: 35593277
- DOI: 10.25259/IJDVL_71_2021
Purified oral cannabidiol for pain management in severe recessive dystrophic epidermolysis bullosa
References
-
- Has C, Bauer JW, Bodemer C, Bolling MC, Bruckner-Tuderman L, Diem A, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol. 2020; 183:614-27
-
- Corroon J, Kight R,. Regulatory status of cannabidiol in the United States: A perspective. Cannabis Cannabinoid Res. 2018; 3:190-4
-
- Robinson E, Murphy E, Friedman A. Knowledge, attitudes, and perceptions of cannabinoids in the Dermatology Community. J Drugs Dermatol. 2018; 17:1273-8
-
- Booz GW,. Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radic Biol Med. 2011; 51:1054-61
-
- Koyama S, Purk A, Kaur M, Soini HA, Novotny MV, Davis K, et al. Beta-caryophyllene enhances wound healing through multiple routes. PLoS One. 2019; 14:e0216104
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
